European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 16:22

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 16:05

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 77, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 15:50

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 77, Status: Authorised

Human medicines European public assessment report (EPAR): Jubereq, denosumab, Date of authorisation: 26/05/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 15:10

Human medicines European public assessment report (EPAR): Jubereq, denosumab, Date of authorisation: 26/05/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 64, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 15:06

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 64, Status: Authorised

Stakeholder Meeting on the transferable data exclusivity voucher (TDEV) for priority antimicrobials, Online, Broadcast, from 12 November 2026, 14:00 (CET) to 12 November 2026, 17:00 (CET)

Submitted by Anonymous (not verified) on 29 October 2026 - 15:03

Stakeholder Meeting on the transferable data exclusivity voucher (TDEV) for priority antimicrobials, Online, Broadcast, from 12 November 2026, 14:00 (CET) to 12 November 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 15:02

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 14:28

Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Ayvakyt, avapritinib, Date of authorisation: 24/09/2020, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 29 October 2026 - 14:10

Human medicines European public assessment report (EPAR): Ayvakyt, avapritinib, Date of authorisation: 24/09/2020, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness